GIP; GLP-1 and glucagon receptor tri-agonist
Retatrutide 0.5 mg subcutaneous once weekly
RETA_SC_0p5MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.22 (-9.21 to 2.93) | 0.58 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -5.31 (-10.93 to 0.23) | 0.73 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.27 (0.26 to 5.29) | 0.40 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.64 (0.11 to 2.49) | 0.82 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.55 (0.05 to 3.16) | 0.82 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.66 (0.34 to 6.71) | 0.49 |